US 2024/0180943 A1 · USE OF BAICALIN IN PREPARATION OF DRUG FOR TREATING TUMOR IRRESPONSIVE TO IMMUNE CHECKPOINT INHIBITORS (ICIs)/UNDERGOING HYPERPROGRESSION

Abstract

A use of baicalin in preparation of a drug for treating a tumor irresponsive to immune checkpoint inhibitors (ICIs)/undergoing hyperprogression is provided, where the non-response to ICIs/hyperprogression of the tumor is caused by excessive Foxp3+Treg cells; the targeted tumor is one selected from the group consisting of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer, and the ICIs is one or a mixture of two or more selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. In the present disclosure, baicalin is used in combination with ICIs to inhibit a number of Foxp3+Treg cells in a tumor to play an anti-tumor sensitization effect, which can effectively treat a variety of tumors irresponsive to ICIs/undergoing hyperprogression caused by excessive Foxp3+Treg cells.

Claims13

Dependent claims

A method of treating a tumor irresponsive to PD-1 immune checkpoint inhibitors (ICIs) and undergoing hyperprogression, wherein the tumor is non-small cell lung cancer and a non-response to the PD-1 ICIs and hyperprogression of the tumor is caused by excessive Foxp3+Treg cells, comprising:

detecting the presence of Foxp3+Treg cells in a non-small cell lung cancer tumor tissue as an indication of hyperprogression, wherein a Foxp3 antibody is used for detecting the presence of Foxp3+Treg cells;
preparing a drug by adding baicalin to a pharmaceutically acceptable adjuvant, wherein a mass percentage content of the baicalin in the drug is 0.05% to 99.5%;
and
administering the drug orally or enterally in combination before or simultaneously with a PD-1 ICI monoclonal antibody, wherein the drug is administered at a dose of 4 mg/d to 1,500 mg/d until a number of Foxp3+Treg cells in the tumor tissue is reduced.

1 more element

Dependencies are inferred from the claim text.

USE OF BAICALIN IN PREPARATION OF DRUG FOR TREATING TUMOR IRRESPONSIVE TO IMMUNE CHECKPOINT INHIBITORS (ICIs)/UNDERGOING HYPERPROGRESSION

Life of this patent

USE OF BAICALIN IN PREPARATION OF DRUG FOR TREATING TUMOR IRRESPONSIVE TO IMMUNE CHECKPOINT INHIBITORS (ICIs)/UNDERGOING HYPERPROGRESSION

Life of this patent

Abstract

Claims13